A detailed history of Vanguard Group Inc transactions in Enochian Biosciences Inc stock. As of the latest transaction made, Vanguard Group Inc holds 5,644,027 shares of ENOB stock, worth $26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,644,027
Previous 3,916,672 44.1%
Holding current value
$26 Million
Previous $18 Million 44.11%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
N/A
1,727,355 Added 44.1%
5,644,027 $26 Million
Q1 2024

May 10, 2024

BUY
N/A
3,526,565 Added 904.0%
3,916,672 $18 Million
Q4 2023

Feb 14, 2024

BUY
$4.3 - $4.7 $510,762 - $558,275
118,782 Added 43.78%
390,107 $1.79 Million
Q3 2023

Nov 14, 2023

BUY
$0.0 - $4.46 $0 - $197,560
44,296 Added 19.51%
271,325 $1.21 Million
Q2 2023

Aug 14, 2023

SELL
$0.4 - $1.3 $38,098 - $123,821
-95,247 Reduced 29.55%
227,029 $129,000
Q1 2023

May 15, 2023

SELL
$0.91 - $1.31 $397,148 - $571,719
-436,427 Reduced 57.52%
322,276 $296,000
Q4 2022

Feb 10, 2023

BUY
$1.03 - $2.13 $3,646 - $7,540
3,540 Added 0.47%
758,703 $781,000
Q3 2022

Nov 14, 2022

BUY
$1.7 - $2.86 $29,794 - $50,124
17,526 Added 2.38%
755,163 $1.37 Million
Q2 2022

Aug 12, 2022

SELL
$1.93 - $8.73 $383,369 - $1.73 Million
-198,637 Reduced 21.22%
737,637 $1.42 Million
Q1 2022

May 13, 2022

SELL
$4.42 - $9.0 $9,264 - $18,864
-2,096 Reduced 0.22%
936,274 $7.73 Million
Q4 2021

Feb 14, 2022

BUY
$6.71 - $12.55 $4.57 Million - $8.55 Million
681,314 Added 265.04%
938,370 $6.84 Million
Q3 2021

Nov 12, 2021

SELL
$4.56 - $7.88 $75,696 - $130,808
-16,600 Reduced 6.07%
257,056 $1.73 Million
Q2 2021

Aug 13, 2021

BUY
$2.94 - $6.79 $804,548 - $1.86 Million
273,656 New
273,656 $1.36 Million

Others Institutions Holding ENOB

About Enochian Biosciences Inc


  • Ticker ENOB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,950,000
  • Market Cap $244M
  • Description
  • Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for au...
More about ENOB
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.